AKT1 and ovarian cancer: Astanehe et al. demonstrated that a loss of p53 function increases the expression of the PI3K p110 isoform in ovarian cancer [33], whilst Thakur et al. identified that ovarian cells that had nonfunctional TP53 and were cisplatin resistant exhibited higher phosphorylation of AKT [34].